NOT-CA-21-111: Notice of Pre-Application Webinar for Acquired Resistance to Therapy Network (ARTNet) and its Coordinating and Data Management Center (RFA-CA-21-052 and RFA-CA-21-053)

Notice of Pre-Application Webinar for Acquired Resistance to Therapy Network (ARTNet) and its Coordinating and Data Management Center (RFA-CA-21-052 and RFA-CA-21-053)

Notice Number:

NOT-CA-21-111

Key Dates

Release Date:

August 18, 2021

Related Announcements

RFA-CA-21-052 - Acquired Resistance to Therapy Network (ARTNet; U54 Clinical Trial Not Allowed)

RFA-CA-21-053 - Coordinating and Data Management Center for Acquired Resistance to Therapy Network (ARTNet; U24 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

The National Cancer Institute (NCI) will hold a pre-application webinar on September 20, 2021, from 1:00 PM to 3:00 PM Eastern Time for the Funding Opportunity Announcements (FOAs) RFA-CA-21-052 "Acquired Resistance to Therapy Network (ARTNet; U54 Clinical Trial Not Allowed)" and RFA-CA-21-053 "Coordinating and Data Management Center for Acquired Resistance to Therapy Network (ARTNet; U24 Clinical Trial Not Allowed)".

NCI staff members involved in managing the Acquired Resistance to Therapy Network (ARTNet) program will assist potential applicants by explaining the goals and objectives of this initiative and answering questions from attendees. Prospective applicants to RFA-CA-21-052 and/or RFA-CA-21-053 are encouraged to submit their questions or comments to Ms. Kim Witherspoon ([email protected]) in advance of the webinar by September 13, 2021. The webinar will not be recorded.

Please include "Pre-application webinar for ARTNet FOAs: question/comment submission” in the subject line of the email for all question/comment submissions.

Webinar Information

To join the Webinar, pre-registration is required through Webex at: https://cbiit.webex.com/cbiit/j.php?RGID=r9c801463ffca7c09cc3098fa36d9c7df

Specific Webinar information including the webinar link will be provided upon registration.

Participation in this webinar, although encouraged, is optional and is not required for the submission of an application in response to RFA-CA-21-052 or RFA-CA-21-053.

Inquiries

Please direct all inquiries to:

Michael Graham Espey, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5690
Email: [email protected]

Jeffrey Hildesheim, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6213
Email: [email protected]

Percy Ivy, M.D.
National Cancer Institute (NCI)
Telephone: 240-276-6565
Email: [email protected]